Resistance to imatinib (IM) and other tyrosine kinase inhibitors (TKI)s is an increasing problem in leukemias caused by expression of BCR-ABL1. As chronic myeloid leukemia (CML) cell lines expressing BCR-ABL1 utilize an alternative non-homologous end-joining pathway (ALT NHEJ) to repair DNA double-strand breaks (DSB)s, we asked whether this repair pathway is a novel therapeutic target in TKI-resistant disease. Notably, the steady state levels of two ALT NHEJ proteins, poly-(ADP-ribose) polymerase 1 (PARP1) and DNA ligase IIIa, were increased in the BCR-ABL1-positive CML cell line K562 and, to a greater extent, in its imatinib-resistant (IMR) derivative. Incubation of these cell lines with a combination of DNA ligase and PARP inhibitors inhibited ALT NHEJ and selectively decreased survival with the effect being greater in the IMR derivative. Similar results were obtained with TKI-resistant derivatives of two hematopoietic cell lines that had been engineered to stably express BCR-ABL1. Together our results show that the sensitivity of cell lines expressing BCR-ABL1 to the combination of DNA ligase and PARP inhibitors correlates with the steady state levels of PARP1 and DNA ligase IIIa, and ALT NHEJ activity. Importantly, analysis of clinical samples from CML patients confirmed that the expression levels of PARP1 and DNA ligase IIIa correlated with the sensitivity to the DNA repair inhibitor combination. Thus, the expression levels of PARP1 and DNA ligase IIIa serve as biomarkers to identify a subgroup of CML patients who may be candidates for therapies that target the ALT NHEJ pathway when treatment with TKIs has failed.
INTRODUCTION
Chronic myelogenous leukemia (CML) is a hematological malignancy characterized by increased and unregulated growth of myeloid cells in the bone marrow (BM) and accumulation of excessive white blood cells. 1, 2 In most cases, this is caused by the expression of the BCR-ABL1 fusion protein, a constitutively active tyrosine kinase (TK). 3, 4 The ABL-specific inhibitor, imatinib mesylate (IM), is currently used as first line therapy for CML. Although responses in chronic phase CML tend to be durable, relapse after an initial response is common in patients with more advanced disease. [5] [6] [7] [8] [9] [10] [11] Approximately 50% of imatinib-resistant (IMR) patients have acquired mutations in BCR-ABL1, 12 particularly within and around the ATP-binding pocket of the ABL kinase domain. Although second generation TK inhibitors (TKI)s inhibit all of the BCR-ABL1 mutants except T315I, resistance to these inhibitors is also being reported. 13, 14 Thus, the development of novel therapies is critically important for patients with acquired resistance to BCR-ABL1-directed TKIs.
Expression of the BCR-ABL1 kinase induces production of reactive oxygen species that, in turn, cause DNA damage including double-strand breaks (DSB)s. [15] [16] [17] [18] [19] [20] Previously, we have shown that CML cells respond to increasing DNA damage with enhanced DNA repair processes. 15, 21 DNA-dependent protein kinase (DNA PK)-dependent non-homologous end joining (NHEJ) is one of the main pathways for repairing DSBs in mammalian cells. It is initiated by binding of the Ku70/86 heterodimer to DSBs, followed by the recruitment of the DNA PK catalytic subunit to form active DNA PK. [22] [23] [24] After protein-mediated end-bridging, the DNA ends are processed by a combination of nucleases and polymerases, and then joined by DNA ligase IV in conjunction with XRCC4 and XLF. [25] [26] [27] Repair of DSBs by this pathway usually results in the addition or loss of few nucleotides at the break site but rarely involves the joining of previously unlinked DNA molecules. In addition to DNA PK-dependent NHEJ, there is a highly error-prone version of NHEJ, alternative (ALT) NHEJ, that is characterized by a high frequency of large deletions, chromosomal translocations and short tracts of microhomologies at the repaired site. 28 We showed recently that the abnormal DSB repair in BCR-ABL1-positive CML was due to reduced activity of DNA PK-dependent NHEJ and increased activity of ALT NHEJ. 29 Furthermore, 'knockdown' of DNA ligase IIIa, a participant in ALT NHEJ, resulted in increased accumulation of unrepaired DSBs and reduced survival, suggesting that ALT NHEJ pathway components, such as poly-(ADP-ribose) polymerase 1 (PARP1) and DNA ligase IIIa, [29] [30] [31] [32] [33] [34] [35] may be novel therapeutic targets in cancer cells that are more dependent on ALT NHEJ for DSB repair.
The recent development of PARP inhibitors, which selectively target the DSB repair defect in hereditary breast cancers, 36, 37 has stimulated interest in the use of DNA repair inhibitors as cancer therapeutics. As DNA ligation is the final step of almost all DNA repair pathways, we used a structure-based drug design approach to identify small molecule inhibitors with different specificities for the three human DNA ligases. 38, 39 As expected, a subset of these inhibitors potentiated the cytotoxicity of DNA-damaging agents, but, interestingly, this effect was more pronounced in cancer cells. 38, 39 As BCR-ABL1-positive CML cells have abnormal DSB repair, 29 we have examined the effect of PARP1 inhibitors on TKIsensitive and -resistant CML cells in the presence or absence of a DNA ligase inhibitor. Our results provide evidence that targeting ALT NHEJ with a combination of DNA ligase and PARP inhibitors is potentially a novel therapeutic strategy for CML patients who fail TKI therapy.
RESULTS
Generation and characterization of IMR BCR-ABL1-positive cell lines IMR derivatives of the CML IM-sensitive (IMS) cell line K562, and the hematopoietic cell lines, Mo7e-P210 and Baf3-P210 that had been engineered to stably express BCR-ABL1 (Supplementary  Figures S1A-C and Supplementary Table S1 ), were selected by growth in IM-containing media. The IMR cell lines, Mo7e-P210 IMR2 and Baf3-P210 IMR, had acquired mutations within BCR-ABL1 resulting in D276G and T315I amino-acid changes, respectively. Notably, these amino-acid changes have been observed in IMR CML patients (Supplementary Table S1 ). 6, 9 While BCR-ABL1 was neither overexpressed nor mutated in the K562 IMR and Mo7e-P210 IMR1 cell lines, the Mo7e-P210 IMR1 cells had increased RAS activation and phosphorylation of AKT compared with Mo7e-P210 (Supplementary Figures S1D-E) , suggesting that activation of parallel signaling pathways may contribute to the IMR of these cells. 40 Importantly, our IMR cell lines recapitulate different mechanisms of resistance to TKIs that have been described in IMR CML patients. 6, 7, 9 Altered expression of DNA repair proteins in IMS and IMR BCR-ABL1-positive cell lines As we had shown previously that the steady-state level of the ALT NHEJ protein, DNA ligase IIIa, was higher in K562 leukemia cells compared with B-cell lines established from normal individuals, 29 we examined the steady-state protein level of key DNA PKdependent and ALT NHEJ proteins in other cell lines expressing BCR-ABL1. In addition to DNA ligase IIIa, the steady-state levels of another ALT NHEJ protein, PARP1, [29] [30] [31] [32] [33] [34] [35] was also elevated in K562 compared with NC10 cells (Po0.05, Figures 1a and b) . The NC10 cells are not genetically related to K562 cells, so the alterations in the steady-state levels of DNA ligase IIIa and PARP1 could be due to intrinsic differences between the cell lines rather than BCR-ABL1 expression. However, the steady-state levels of DNA ligase IIIa and PARP1 were also increased in the derivatives of the hematopoietic cell lines, Mo7e and Baf3, that express BCR-ABL1 (Po0.05, Figure 1c ) albeit to a lesser extent than in the K562 cells. Thus, we conclude that BCR-ABL1 expression does result in increased steady-state levels of DNA ligase IIIa and PARP1. Although the IMR derivative of K562 expressed similar levels of DNA ligase IIIa and PARP1 compared with the parental K562 cells (Figure 1b) , the steady-state levels of these proteins were significantly increased in the IMR derivatives of Mo7e-P210 and Baf3-P210 compared with their IMS counterparts (Po0.05, Figure 1c ). As we reported previously, 29 there was a small reduction in the steady-state levels of the DNA PK-dependent NHEJ factors, DNA ligase IV and Ku70, in K562 cells compared with NC10 cells (Figures 1a and b) . There was, however, a significant decrease in Ku70 levels in the K562 IMR cells (Po0.05; Figures 1a  and b) . No significant changes in the levels of DNA ligase IV and Ku70 were observed in the IMS and IMR derivatives of Mo7e-and Baf3-expressing BCR-ABL1 compared with their parental cells (Figure 1c ).
BCR-ABL1-positive cell lines are hypersensitive to the combination of DNA ligase and PARP inhibitors As all the BCR-ABL1-positive cell lines have increased steady-state levels of DNA ligase IIIa and PARP1, we asked whether they exhibited increased sensitivity to inhibitors of these proteins. In the absence of a DNA ligase IIIa-specific inhibitor, we examined the effects of L67, which inhibits DNA ligases I and IIIa but not DNA ligase IV 38 and the PARP inhibitor NU1025. 41 None of the hematopoietic cell lines, Mo7e, Mo7e-P210 (Supplementary Figures  S2A-B) , Baf3 or Baf3-P210 (data not shown), exhibited significantly increased sensitivity to either L67 or NU1025 alone, with the agents reducing growth and viability of all cell lines with IC50s of about 3.5 and 500 mM, respectively. This prompted us to examine the effect of lower concentrations of L67 (0.3 mM) and NU1025 (50 mM), alone and in combination, in colony survival assays. Under these conditions, NC10, K562 and K562 IMR were relatively insensitive to L67 alone (Figure 2a ), whereas only K562 IMR cells exhibited significantly increased sensitivity to NU1025 (Po0.05; Figure 2a ). Notably, both K562 and, to an even greater extent, K562 IMR cells, exhibited significantly increased hypersensitivity to the combination of DNA repair inhibitors compared with either agent alone and NC10 cells (Po0.05; Figure 2a ). In similar experiments with the BCR-ABL1-transfected cell lines, both IMR derivatives of Mo7e-P210 and the IMR derivative of Baf3-P210 also exhibited significantly reduced colony survival with the repair inhibitor combination (Po0.05; Figure 2b ). To determine whether the activity of L67 can be specifically attributed to its effects on DNA ligase IIIa, colony survival assays were performed following siRNA knockdown of DNA ligase IIIa. Reducing the steady-state levels of DNA ligase IIIa by about 50% in combination with PARP inhibitor (Figure 2c ) resulted in a similar reduction in colony survival as the treatment with L67 and PARP inhibitor (Figure 2d ), demonstrating that the activity of L67 is due to its inhibition of DNA ligase IIIa.
Combination of DNA repair inhibitors increase DSBs and inhibits ALT NHEJ in BCR-ABL1-positive cell lines To determine whether the altered levels of NHEJ proteins in cells that express BCR-ABL1 result in abnormal repair of DSBs, we first measured the percentage of cells with more than 3 gH2AX foci/ cell, as an indicator of unrepaired spontaneous DSBs. 42 As expected, the cell lines expressing BCR-ABL1 had more spontaneous DSBs than the control cell lines (Figures 3a-c) . 29 Notably, all of the IMR derivatives had significantly higher levels of spontaneous DSBs compared with IMS cell lines, suggesting that these cells have higher levels of endogenous DNA-damaging agents and/or a more pronounced DNA repair defect. Treatment of the cells with the DNA repair inhibitor combination increased the number of unrepaired DSBs with the effect being the greatest in the cells expressing BCR-ABL1 (Po0.05; Figures 3a-c). As both PARP1 and DNA ligase IIIa participate in the repair of single-strand breaks (SSB)s as well as in ALT NHEJ, [29] [30] [31] [32] [33] [34] [35] inhibition of these enzymes may increase the levels of unrepaired DSBs by inhibiting the repair of DSBs by ALT NHEJ, in addition to increasing the number of replication-induced DSBs as a consequence of reduced SSB repair.
To measure the repair of DSBs by NHEJ and determine the effect of the DNA repair inhibitor combination, we used a plasmidbased repair assay with an EcoR1-linearized plasmid substrate. 21 The overall level of plasmid repair was significantly higher in both K562 cells and its IMR derivative compared with the NC10 cells with increases in both accurate (blue colonies) and, to an even greater extent, inaccurate (white colonies) repair (Figure 4a ). Similar results were obtained in the IMS and IMR derivatives of the hematopoietic cell lines, Mo7e and Baf3, that express BCR-ABL1, although the increase in inaccurate repair was less in the Mo7e derivatives ( Figure 4a ).
As the white colonies may be a result of either small insertions or deletions generated by DNA PK-dependent NHEJ or larger deletions that are characteristic of ALT NHEJ, the plasmids from the white colonies were sequenced to detect the molecular signatures, microhomologies and deletion size at the repair site, which distinguish ALT from DNA PK-dependent NHEJ. As expected, the average size of DNA deletions ( Figure 4b ) and frequency of microhomologies (X2 bp, Figure 4c ) in repaired plasmids was higher in the K562 cells compared with NC10, indicating increased ALT NHEJ activity. 29 There was no significant difference in the average size of deletions generated by the IMS and IMR derivatives of K562 (Figure 4b ) but there was an increase in the frequency of microhomologies at the repair site in the IMR derivative (Figure 4c ). It is possible that the increase in microhomology-mediated repair events is due to the reduced levels of Ku70 in the IMR derivative of K562 (Figures 1a and b) . In similar experiments with the BCR-ABL1-transfected hematopoietic cell lines, the average size of deletions and the frequency of microhomology-mediated repair events was higher in the IMS lines compared with the parental cells and even higher in the IMR cell lines (Figures 4d and e) . Thus, the contribution of ALT NHEJ to DSB repair correlates with the extent of PARP1 and DNA ligase IIIa overexpression in these cell lines. Treatment with the DNA repair inhibitor combination reduced the abnormalities in DNA repair observed in IMS and IMR cells, so that deletion size and the frequency of microhomology-mediated repair resembled that of normal cells (Figures 4b-e) .
Taken together, our results indicate that the cell lines expressing BCR-ABL1 are more dependent on ALT NHEJ for DSB repair than comparable normal cells, and that the dependence upon ALT NHEJ increases during the acquisition of resistance to IM. As the repair of DSBs by ALT NHEJ is error-prone, resulting in large deletions and chromosomal translocations, 28 there should be increased genomic instability in IMS cells and to an even greater extent in IMR cells. Thus, we analyzed genomic deletions and insertions in Mo7e-P210 IMR1, Mo7e-P210 and Mo7e cells, using High-Resolution Discovery 1M comparative genomic hybridization (CGH) human microarrays. Using this approach, we detected six deleted regions, equivalent to approximately 320 Mb of DNA, in Mo7e-P210 cells compared with Mo7e cells (Figures 5a  and c) . The Mo7e-P210 IMR1 cells had acquired seven additional deletions, equivalent to approximately 420 Mb of DNA, compared with the Mo7e-P210 cells (Figures 5b and c) . Thus, 15 large deletion events occurred, resulting in the loss of 720 Mb of DNA, during the transition from BCR-ABL1-negative Mo7e cells to an IMR derivative expressing BCR-ABL1. In addition, our CGH analysis also showed amplification events: two regions (equivalent approximately to 40 Mb) were amplified in Mo7e-P210 compared with Mo7e. In contrast, the transition from Mo7e-P210 to Mo7e-P210 IMR1 involved an additional two amplifications (equivalent approximately to 30 Mb). Thus, in transitioning from BCR-ABL1-negative cells (Mo7e) to Mo7e-P210 IMR1, there was a gain of DNA in four regions (equivalent to 70 Mb).
Overexpression of DNA ligase IIIa and PARP1 in primary cells from BCR-ABL1 CML patients correlates with sensitivity to the DNA repair inhibitor combination Our cell culture studies suggest that the expression levels of DNA ligase IIIa and PARP1 can be used as biomarkers to identify leukemia cells from CML patients, which will be specifically hypersensitive to the combination of L67 and NU1025. To test this hypothesis, we examined BM mononuclear cells (BMMNC) from 8 IMS and 11 IMR CML patients ( Figure 6a ). We next determined the sensitivity of the BMMNC from the CML patients to the combination of L67 and PARP inhibitors in colony survival assays using NBM as control (Table 1 , Figure 6b, Supplementary Figure S3B ). Based on their sensitivity to L67 and PARP inhibitors, the leukemia cells can be divided into three groups: BMMNC that were (i) hypersensitive to the combination of L67 and NU1025 with a significant reduction in colony formation compared to either inhibitor alone (PT2, 10A, 10B, 11, 12, 14, 17, 18, 19; Po0.005); (ii) partially sensitive to the inhibitor combination due to inhibition of colony formation by either the DNA ligase or PARP inhibitor (PT1, 8, 9, 13, 15; Po0.05); and (iii) insensitive to the combination (PT3, 4, 6, 7, 16) . Notably, 90% of the BMMNC samples that were hypersensitive to the DNA repair inhibitor combination had increased levels of both DNA ligase IIIa and PARP1 (Po0.05, Figure S3B) , whereas all insensitive BMMNC samples had levels of DNA ligase IIIa and PARP1 comparable to those of NBM (Table 1, Figures 6a and b, Supplementary Figure  S3B ). Hypersensitivity to the combination of DNA repair inhibitors was observed in all samples from patients in blast crisis (Table 1) . Interestingly, BMMNC from PT10A, whose disease rapidly progressed from IMS chronic phase to IMR blast crisis (PT10B), exhibited similar sensitivity to the combination of DNA repair inhibitors at both stages of the disease (Table 1, Figures 6a and b,  Supplementary Figure S3B ).
DISCUSSION
Alterations in the network of pathways that respond to DNA damage and maintain genome stability are presumed to underlie the genomic instability of cancer cells and their increased sensitivity to cytotoxic DNA-damaging agents. Although abnormalities in the DNA damage response are poorly defined, particularly in sporadic cancers, they are potential targets for the development of therapeutics that either alone or in combination with cytotoxic DNA-damaging agents, preferentially enhance killing of cancer cells. This rationale led to the development of PARP inhibitors that specifically kill cancer cells in inherited forms of breast cancer, because the cancer but not normal cells have a defect in the repair of DSBs. 41 There is compelling evidence that the repair of DSBs in BCR-ABL1-positive CML cells is abnormal. 17, 21, 29 We have shown previously that these cells preferentially utilize a highly error-prone ALT NHEJ pathway that likely contributes to disease progression by causing increased genome instability. 29 The increased contribution of the ALT NHEJ pathway to DSB repair in the BCR-ABL1-positive CML cells is due, at least in part, to increased steady-state levels of the ALT NHEJ factors, DNA ligase IIIa and WRN. 29 Although IM and other related TKIs are an effective frontline therapy for BCR-ABL1-positive CML, there is a lack of effective treatment options for patients whose disease has become resistant to TKIs. 13, 14 This prompted us to examine the DNA repair properties of four BCR-ABL1-positive cell lines that were selected for IMR by long-term culture in the presence of IM.
In accordance with what is observed in patients with IMR CML, 6,9 two of the IMR cell lines had acquired mutations in BCR-ABL1, whereas two had not. Notably, the mutations in BCR-ABL1 resulted in amino-acid changes, D276G and T315I, that have been observed in IMR CML patients. 6, 9 Using a plasmid-based NHEJ assay, we found that the contribution of ALT NHEJ to DSB repair was even higher in the IMR cell lines than previously observed in IMS cell lines 29 and correlated with increased expression of the ALT NHEJ factors, PARP1 and DNA ligase IIIa in the three IMR hematopoietic cell lines transfected with BCR-ABL1. The increased steady-state level of endogenous DSBs in BCR-ABL1-positive cells is due, at least in part, to increased levels of reactive oxygen species. [15] [16] [17] [18] [19] [20] It is also likely that inefficient DSB repair by ALT NHEJ contributes to the increased number of unrepaired DSBs. 15, 21, 29 In the IMR cell lines, there were even higher levels of endogenous DSBs, presumably reflecting the larger role of the inefficient errorprone ALT NHEJ pathway in DSB repair. The increased dependence of BCR-ABL1-positive cells and, in particular, the IMR cells on ALT NHEJ for the repair of DSBs makes this pathway an attractive potential cancer cell-specific therapeutic target. As PARP1 participates both in the repair of SSBs and ALT NHEJ, [29] [30] [31] [32] [33] [34] [35] we postulated that PARP inhibitors would sensitize cells with increased dependence on ALT NHEJ because they concomitantly cause replication-associated DSBs by blocking SSB repair 36, 37 and inhibit PARP1-dependent ALT NHEJ. Despite the Notably, a combination of the DNA ligase and PARP inhibitors did preferentially kill all the IMR BCR-ABL1-positive cell lines, including the cell line expressing the T315I version of BCR-ABL1, which is refractory to all current TKIs. 13, 14 As treatment with the repair inhibitor combination, whose activity is dependent upon DNA ligase IIIa inhibition, also increased the level of DSBs and inhibited ALT NHEJ, it appears that the hypersensitivity of the IMR cell lines is due, at least in part, to the targeting of the ALT NHEJ pathway by the repair inhibitors. Like PARP1, DNA ligase IIIa participates in both SSB repair and ALT NHEJ. [29] [30] [31] [32] [33] [34] [35] Thus, it is possible that partial inhibition of two components in the same pathway has an additive effect in terms of inhibition of the overall repair pathways of ALT NHEJ and SSB repair. Alternatively, the efficacy of the repair inhibitor combination may also be due to the targeting of other cellular transactions in addition to ALT NHEJ and SSB repair. For example, the PARP inhibitor may target cellular functions involving other members of the PARP family 43 in addition to PARP1, whereas base excision repair and mitochondrial DNA metabolism will also be impacted by inhibition of DNA ligase IIIa. 44, 45 Although detectable, the contribution of ALT NHEJ to DSB repair is normally minor in cells with a functional DNA PKdependent NHEJ pathway 28 with Ku having a major role in suppressing ALT NHEJ. 46 Except for the IMR derivative of the K562 leukemia cell line, the levels of Ku in cell lines expressing BCR-ABL1 were not significantly reduced. It seems unlikely that the increased contribution of ALT NHEJ to DSB repair is due solely to the increased steady-state levels of DNA ligase IIIa and PARP1, suggesting that, during the acquisition of IMR, there are other changes that reduce the activity of DNA PK-dependent NHEJ. As the DNA end-binding activity of Ku is inhibited by oxidative stress, 47 it is conceivable that the reduced activity of DNA PKdependent NHEJ in IMS and IMR cells expressing BCR-ABL1 may be due to the increased levels of reactive oxygen species. [15] [16] [17] [18] [19] [20] Alternatively, DNA PK-dependent NHEJ activity may be reduced in IMS and IMR cells expressing BCR-ABL1 because of increased end resection, a common step in both homologous recombination and ALT NHEJ that inhibits DNA end-binding by Ku. [48] [49] [50] Irrespective of the exact mechanism, the results of our cell line studies demonstrate that IMR cells expressing BCR-ABL1 are more dependent upon DNA ligase IIIa-dependent ALT NHEJ for the repair of DSBs, and that PARP1 and DNA ligase IIIa expression levels may serve as biomarkers to identify patients with TKIresistant CML whose disease will respond to therapies that target ALT NHEJ. Our analysis of primary samples from CML patients confirmed that overexpression of both PARP1 and DNA ligase IIIa correlated with hypersensitivity to the combination of DNA ligase and PARP inhibitors in 90% of patients with both IMS and IMR disease. As we observed elevated steady-state levels of DNA ligase Table 1 . Clinical and molecular features of BCR-ABL1 CML patients
Abbreviations: IMR, imatinib resistant; IMS, imatinib sensitive; N, no; ND, not determined; Y, yes. IIIa and PARP1 in the absence of BCR-ABL1 mutations in our cell line studies and in BMMNC from IMS and IMR CML patients, these changes are not absolutely dependent on BCR-ABL1 mutations. Among the nine BMMNC samples from patients with IMR disease, three had acquired mutations in BCR-ABL1 with two of these encoding the T315I version of BCR-ABL1 that is resistant to all current TKIs. In accordance with our cell culture studies, the BMMNC samples expressing BCR-ABL1 T315I had elevated steadystate levels of both DNA ligase IIIa and PARP1, and were sensitive to the combination of DNA repair inhibitors. Other mechanisms of resistance, including BCR-ABL1 amplification and activation of parallel signaling pathways, that have been described in about 50% of CML patients with TKI-resistant disease 6, 7, 9, 40 presumably also contribute to the elevated levels of DNA ligase IIIa and PARP1. Importantly, 50% of BMMNC from patients with IMR disease and all patients in blast crisis had elevated steady-state levels of DNA ligase IIIa and PARP1, and were hypersensitive to the DNA repair inhibitor combination. Taken together, these results provide strong evidence that a DNA repair abnormality, increased dependence upon ALT NHEJ, can be identified and targeted in a significant fraction of CML patients, who have acquired resistance to the frontline therapy and for whom there are currently no good treatment options. There is emerging evidence that this abnormality in DSB repair may also occur in a significant fraction of cell lines derived from different solid tumors 38 and in forms of breast cancer with acquired or intrinsic resistance to antiestrogens. 51 Thus, the strategy of targeting ALT NHEJ may also be applicable to a wide range of solid tumors.
MATERIALS AND METHODS

Cell culture
The BCR-ABL1-positive human CML cell line, K562, was from ATCC (Manassas, VA, USA). NC10, a BCR-ABL1-negative human lymphoblastoid cell line established from normal lymphocytes was obtained from Dr Gazdar (University of Texas Southwestern, Dallas, TX, USA). Mo7e, a BCR-ABL1-negative human myeloid leukemia cell line and Mo7e stably expressing BCR-ABL1 (Mo7e-P210) were obtained from Dr Van Etten (Tufts University, Boston, MA, USA). Baf3, a BCR-ABL1-negative murine hematopoietic progenitor cell line and Baf3 stably expressing BCR-ABL1 (Baf3-P210) were obtained from Dr Deininger (Oregon Health and Science University, Portland, OR, USA). IMR derivatives were generated by growing IMS cell lines in 2 mM IM. Different clones (K562 IMR, Mo7e-P210 IMR1, Mo7e-P210 IMR2 and Baf3-P210 IMR) were selected by serial dilution under IM selection (Supplementary Figure S1A-C and Supplementary Table S1 ). All cells were cultured in RPMI 1640 (Sigma-Aldrich, St Louis, MO, USA) with 4 mM L-glutamine (Cellgro, Manassas, VA, USA), 1% penicillin-streptomycin (Invitrogen, Carlsbad, CA, USA) and 10% fetal bovine serum (Sigma-Aldrich) at 37 1C in 5% CO 2 , supplemented with 10 ng/ml GM-CSF and IL-3 for Mo7e and Baf3, respectively (Millipore, Temecula, CA, USA). Media for IMR cell lines included 2 mM IM. NBM samples and BMMNC from IMS and IMR CML patients (Supplementary Figure S3A , Table 1 ) were cultured in HPGM (Lonza, Walkersville, MD, USA) supplemented with 1 ng/ml G-CSF (Calbiochem, Merck, Gibbstown, NJ, USA), 25 ng/ml SCF (Calbiochem) and 10 ng/ml GM-CSF, IL-3, and IL-6 (Millipore).
Colony survival assays
Cells were seeded at a density of 700 cells/well in methylcellulose-based medium in the presence of the DNA ligases I and III inhibitor, L67 (0.3 mM), the PARP inhibitor, NU1025 (50 mM); L67 and NU1025 or IM (1-4 mM) for approximately 10 days. Colonies were stained overnight with 2-(4-iodophenyl)-3-(4-nitrophenyl)-5-phenlytetrazolium chloride (1 mg/ml, Sigma-Aldrich) before counting using an automated image analysis system (Omincon FAS IV, BIOSYS GmbH, Karben, Germany). Immunofluorescence staining Cells (200 000) were treated for 72 h with L67 (0.3 mM) and/or NU1025 (50 mM), washed with PBS, cytospun, fixed in 1% paraformaldehyde (P-6148; Sigma-Aldrich) for 10 min, permeabilized in 70% EtOH for 10 min and then blocked for 1 h in 10% fetal bovine serum-TBS-Tween 20 (0.2%). After washing, slides were incubated for 1 h with anti-phospho-histone H2AX (S139; 1:100; Millipore) and then with DyLight 594 anti-mouse secondary antibodies for 1 h (1:200; KPL, Gaithersburg, MD, USA). Slides were washed and dried before counterstaining with 4',6-diamidino-2-phenylindole (Vector Laboratories, Burlingame, CA, USA) and then examined using a Nikon fluorescent microscope Eclipse 80i (100X/1.4 oil, Melville, NY, USA). Images of at least 50 cells/slide were captured using a CCD (chargecoupled device) camera and the imaging software NIMS Elements (BR 3.00, Nikon).
RNA isolation
Total RNA was extracted from cultured cells ( cDNA Sequencing Using procedures described previously, 52 a direct sequencing approach encompassing the entire ABL kinase and ATP-loop domain (corresponding to amino acids 242-395) was performed on cDNA products from RT-PCR using forward (5 0 -CATCACCATGAAGCACAAGC-3 0 ) and reverse (5 0 -GCTGTG TAGGTGTCCCCTGT-3 0 ) primers.
Immunoblotting
Protein extractions were performed without the use of a detergent using the CelLytic NuClear Extraction Kit (Sigma-Aldrich) according to the manufacturer's protocol. Proteins were separated by SDS-PAGE through 4-10% gradient gels and then transferred to PVDF membranes. After blocking, membranes were incubated with primary; rabbit DNA ligase IIIa (1:1000, Sigma-Aldrich), mouse PARP1 (1:1000, eBioscience, San Diego, CA, USA), DNA Ligase IV, Ku70 (1:1000, Santa Cruz, Santa Cruz, CA, USA) or b-Actin (1:5000, Abcam, Cambridge, MA, USA), followed by secondary antibodies; HRP goat anti-rabbit (1:2000) or anti-mouse (1:5000, Santa Cruz). Antigen-antibody complexes were detected by enhanced chemiluminescence and quantified by scanning non-saturated luminograms using Quantity One software (version 4.6., BioRad, Hercules, CA, USA).
Plasmid-based NHEJ repair assay
EcoR1-linearized pUC18 plasmids (ThermoScientific, Glen Burnie, MD, USA) were transfected into cells using Amaxa Nucleofector Kit V. Plasmid DNA was extracted (Qiagen Plasmid Mini Kit) and transformed into E. coli strain DH5a (Invitrogen). After plating on agar plates containing X-gal and IPTG, the number of white (misrepaired) and blue (correctly repaired) colonies were counted. Plasmid DNA from the white (misrepaired) colonies was characterized by PCR amplification of the breakpoint region using forward (5 0 -CGGCATCAGAGCAGATTGTA-3 0 ) and reverse (5 0 -TGGATAACCGTATT ACCGCC-3 0 ) primers followed by DNA sequencing (Genomics core facility, University of Maryland School of Medicine, Baltimore, MD, USA).
Comparative genomic hybridization
Genomic DNA was isolated from frozen cell pellets using DNeasy tissue mini kit (Qiagen) following the manufacturer's protocol. Sample labeling was performed following Agilent's recommendation for 244K array CGH.
